Psychiatric Devices: Medtronic OCD Approval, Depression Trial Announced
This article was originally published in The Gray Sheet
Executive Summary
The medical device industry took another step into the field of psychiatry Feb. 19 with FDA's humanitarian device exemption of Medtronic's Reclaim deep brain stimulator for treating patients with severe obsessive-compulsive disorder
You may also be interested in...
FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.
FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects
Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.
Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis